title: [Novel molecular-targeted agents for GIST(Regorafenib etc.)].
abstract: Gastrointestinal stromal tumors(GIST)are the most frequent sarcoma arising from gastrointestinal tract. Imatinib and sunitinib are proven to be efficacious against GIST and become standard of care. Moreover several novel molecular-targeted agents are in development. Regorafenib significantly improved progression-free survival in patients with GIST who were treated with imatinib and sunitinib in a randomized phase III trial and is considered a new standard option.
authors.affiliation: Dept. of Breast and Medical Oncology, National Cancer Center Hospital East, Japan.
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Naito
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Doi
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy*; D006801:Humans; D058990:Molecular Targeted Therapy
chemical_list: D000970:Antineoplastic Agents